Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database.
Feasibility of Capturing Cancer Treatment Data in the Utah All-Payer Claims Database.
复制标题
DOI：
10.1200/cci.19.00027
复制
发表时间：
2019-10-01
影响因子：
4.2
通讯作者：
Sweeney, Carol
中科院分区：
文献类型：
--
作者：
Hashibe, Mia;Ou, Judy Y;Sweeney, Carol
目的：治疗数据的不完整性是癌症登记数据公认的局限性。全付款人索赔数据库 (APCD) 是一种工具，各州用它来获取跨系统和付款人的医疗保健信息。我们将犹他州癌症登记处 (UCR) 记录与犹他州全州 APCD 关联起来，并评估了这种关联如何改善癌症治疗信息的获取。 方法：我们使用 LinkPlus 软件将诊断并向 UCR 报告的癌症与 2013 年和 2014 年犹他州 APCD 索赔关联起来。对于乳腺癌或结直肠癌患者，完成手动提取，为从索赔中获得的治疗数据提供金标准比较。 结果：在与 APCD 相关的 10,759 例可报告癌症发生中，索赔确定了接受登记处未知治疗的其他癌症患者，将化疗治疗比例从 23.7% 增加到 27.6%，激素治疗从 14.1% 增加到 18.8%，免疫治疗从 14.1% 增加到 18.8%。 4.3% 降至 13.2%，放射治疗从 24.9% 降至 27.5%。与抽象金标准相比，APCD 提高了治疗变量的敏感性。值得注意的是，当使用 APCD 索赔数据进行增强时，激素疗法对乳腺癌的敏感性从 78.6% 增加到 95.2%。然而，单独的 APCD 并没有达到像通过传统登记方法收集的数据那样高的治疗数据特异性。 结论：据我们所知，这是第一项研究，表明将癌症登记数据与覆盖多家保险公司的全州理赔数据库联系起来可以改善癌症治疗数据的收集。癌症登记和APCD数据的链接可以提高癌症登记治疗数据的全面性。
PURPOSE: Incompleteness of treatment data is a recognized limitation of cancer registry data. An all-payer claims database (APCD) is a tool that states use to capture health care information across systems and payer. We linked the Utah Cancer Registry (UCR) records to Utah's statewide APCD and evaluated how this linkage led to improvements in the capture of cancer treatment information.METHODS: We linked cancers diagnosed and reported to the UCR with Utah APCD claims for the calendar years 2013 and 2014 using LinkPlus Software. For patients with breast or colorectal cancers, manual abstraction was completed to provide a gold-standard comparison for the treatment data obtained from the claims.RESULTS: Among 10,759 reportable cancer occurrences linked to the APCD, the claims identified additional patients with cancer who received therapies that had been unknown to the registry, increasing the proportion treated with chemotherapy from 23.7% to 27.6%, hormone therapy from 14.1% to 18.8%, immunotherapy from 4.3% to 13.2%, and radiation therapy from 24.9% to 27.5%. The APCD increased the sensitivity of treatment variables compared with the abstraction gold standard. Notably, sensitivity of hormonal therapy for breast cancer increased from 78.6% to 95.2% when augmented with APCD claims data. However, the APCD alone did not achieve as high specificity for treatment data as did the data collected through traditional registry methods.CONCLUSIONS: This is the first study, to our knowledge, showing that linking cancer registry data with a statewide claims database that covers multiple insurance companies improves cancer treatment data collection. Linking of cancer registry and APCD data can improve comprehensiveness of cancer registry treatment data.